Revolution Medicines, Inc. (RVMD)
211.58
+2.12
(+1.01%)
USD |
NASDAQ |
Aug 24, 16:00
211.40
-0.18
(-0.09%)
After-Hours: 19:52
Revolution Medicines Total Liabilities (Quarterly) : 1.717B for June 30, 2026
Total Liabilities (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 1.717B |
| March 31, 2026 | 753.82M |
| December 31, 2025 | 777.09M |
| September 30, 2025 | 655.02M |
| June 30, 2025 | 564.20M |
| March 31, 2025 | 287.20M |
| December 31, 2024 | 338.20M |
| September 30, 2024 | 196.70M |
| June 30, 2024 | 189.59M |
| March 31, 2024 | 182.90M |
| December 31, 2023 | 262.40M |
| September 30, 2023 | 146.77M |
| June 30, 2023 | 142.87M |
| March 31, 2023 | 121.03M |
| December 31, 2022 | 153.00M |
| September 30, 2022 | 144.49M |
| Date | Value |
|---|---|
| June 30, 2022 | 133.96M |
| March 31, 2022 | 131.78M |
| December 31, 2021 | 163.39M |
| September 30, 2021 | 96.77M |
| June 30, 2021 | 89.04M |
| March 31, 2021 | 89.07M |
| December 31, 2020 | 112.16M |
| September 30, 2020 | 90.00M |
| June 30, 2020 | 93.46M |
| March 31, 2020 | 69.02M |
| December 31, 2019 | 78.83M |
| September 30, 2019 | |
| June 30, 2019 | |
| March 31, 2019 | |
| December 31, 2018 | 76.84M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| Tango Therapeutics, Inc. | 49.35M |
| Erasca, Inc. | 73.18M |
| Arrowhead Pharmaceuticals, Inc. | 1.646B |
| Intellia Therapeutics, Inc. | 129.46M |
| Beam Therapeutics, Inc. | 318.91M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 4.323B |
| Shareholders Equity (Quarterly) | 2.606B |
| Debt to Equity Ratio | 0.4568 |
| Current Ratio | 11.38 |
| Net Debt Paydown Yield | -0.53% |